Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report 2026

The non-radiographic axial spondyloarthritis therapeutic market size has grown rapidly in recent years. It will grow from $1.04 billion in 2025 to $1.15 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increasing recognition of non-radiographic axial spondyloarthritis, limitations of conventional NSAID therapy, improved diagnostic criteria adoption, growing rheumatology specialty care access, expansion of biologic drug availability.

The non-radiographic axial spondyloarthritis therapeutic market size is expected to see rapid growth in the next few years. It will grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising adoption of JAK inhibitor therapies, growing focus on personalized rheumatology care, expansion of early-stage intervention protocols, increasing patient awareness and diagnosis rates. Major trends in the forecast period include increasing adoption of biologic disease-modifying therapies, rising use of IL-17 and TNF inhibitors, growing focus on early disease intervention, expansion of targeted small molecule treatments, enhanced emphasis on long-term disease control.

The increasing number of clinical trials is expected to drive the growth of the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market going forward. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy, and potential side effects of medical treatments or interventions. The rise in clinical trials is fueled by the growing demand for innovative and personalized therapies that require thorough testing for both safety and effectiveness. Clinical trials support nr-axSpA therapeutics by providing evidence-based validation of treatment efficacy and safety in early-stage disease, guiding regulatory approvals and facilitating clinical adoption. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based organization collaborating with government and NHS bodies to improve patient access to new treatments, the total number of industry clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Therefore, the rising number of clinical trials is propelling the growth of the nr-axSpA therapeutic market.

Key companies operating in the nr-axSpA therapeutic market are focusing on developing innovative solutions, such as dual IL-17A/IL-17F biologic inhibitors and high-convenience delivery formats, to address increasing diagnosis rates, earlier disease recognition, the need for faster and more comprehensive inflammatory control, and patient preferences for less frequent or more convenient dosing. Dual IL-17A/IL-17F biologic inhibitors are monoclonal antibodies that selectively block both IL-17A and IL-17F cytokines, helping manage nr-axSpA by reducing inflammation, pain, stiffness, and structural progression. For instance, in September 2024, UCB S.A. (Union Chimique Belge Société Anonyme), a Belgium-based global biopharmaceutical company, launched BIMZELX in the U.S. for adults with active nr-axSpA following FDA approval. BIMZELX is a humanized IgG monoclonal antibody that neutralizes both IL-17A and IL-17F, providing broader suppression of IL-17-mediated pathways compared with traditional TNF inhibitors or single-target IL-17 therapies. In addition to nr-axSpA, BIMZELX is indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, meeting the evolving treatment needs of patients with inflammatory diseases.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its immunology portfolio by incorporating DICE's oral IL-17 inhibitors for autoimmune diseases, enhancing its capability to address chronic inflammatory conditions with innovative, patient-friendly oral therapies. DICE Therapeutics is a US-based biopharmaceutical company that develops oral IL-17 antagonists, including DC-806 and DC-853, for the treatment of nr-axSpA and other autoimmune disorders.

Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc, Johnson and Johnson, AbbVie Inc, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc, Biogen Inc, Daiichi Sankyo Company Limited, UCB SA, Mochida Pharmaceutical Co Ltd, Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co Ltd, Qyuns Therapeutics Co Ltd, Sandoz Group AG, Boehringer Ingelheim GmbH, Roche Holding AG.

North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2025. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-radiographic axial spondyloarthritis therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the non-radiographic axial spondyloarthritis therapeutic market by increasing costs of imported biologics, active pharmaceutical ingredients, injectable delivery systems, and specialty drug manufacturing inputs. North America and Europe are most affected due to reliance on imported biologic formulations and cold-chain logistics, while Asia-Pacific faces higher costs related to biosimilar production and clinical trial materials. These tariffs are raising treatment costs and slowing patient access to advanced therapies. At the same time, they are encouraging domestic biologics manufacturing, regional biosimilar development, and localized pharmaceutical supply chains.

The non-radiographic axial spondyloarthritis therapeutic market research report is one of a series of new reports that provides non-radiographic axial spondyloarthritis therapeutic market statistics, including non-radiographic axial spondyloarthritis therapeutic industry global market size, regional shares, competitors with a non-radiographic axial spondyloarthritis therapeutic market share, detailed non-radiographic axial spondyloarthritis therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the non-radiographic axial spondyloarthritis therapeutic industry. This non-radiographic axial spondyloarthritis therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-radiographic axial spondyloarthritis therapeutics refer to treatments aimed at managing symptoms and slowing disease progression in patients who do not show visible joint damage on X-rays. These treatments primarily include NSAIDs, biologic therapies (such as TNF and IL-17 inhibitors), and JAK inhibitors. The primary goal is to reduce inflammation, improve function, and prevent the development of radiographic changes in the spine and joints.

The primary types of non-radiographic axial spondyloarthritis therapies include non-steroidal anti-inflammatory drugs (NSAIDs), biologics, small molecule therapies, and corticosteroids. NSAIDs are medications that alleviate inflammation, pain, and fever by inhibiting enzymes involved in prostaglandin production. Treatments are administered via oral, injectable, and topical routes and are used by end users including hospitals, ambulatory surgical centers, and homecare settings.

The non-radiographic axial spondyloarthritis therapeutic market consists of sales of TNF inhibitors, JAK inhibitors, non-steroidal anti-inflammatory drugs, and IL-23 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.